CRISPR/Cas9 in cancer therapy: A review with a special focus on tumor angiogenesis

Hariprabu, Krishnasamy Naidu Gopal; Muthusamy, Sathya; Vimalraj, Selvaraj

doi:10.1016/j.ijbiomac.2021.10.029

Cited by 14 publications

(13 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Proper identification of the respective roles of the different EC Cx will require the experimental testing of novel functional assays, providing conditions close to those prevailing in an in vivo tumor setting. Future investigations will indicate whether any such assay [ 48 , 49 , 50 , 51 , 52 ] can be designed to faithfully and simultaneously address these requirements. Further unravelling of the cell and molecular mechanisms which link Cx37 to tumoral angiogenesis and growth should provide novel insights to promote the development of innovative anti-tumoral treatments.…”

Section: Discussionmentioning

confidence: 99%

Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth

Sathiyanadan

Alonso

Domingos-Pereira

et al. 2022

IJMS

View full text Add to dashboard Cite

Connexin37 (Cx37) and Cx40 form intercellular channels between endothelial cells (EC), which contribute to the regulation of the functions of vessels. We previously documented the participation of both Cx in developmental angiogenesis and have further shown that loss of Cx40 decreases the growth of different tumors. Here, we report that loss of Cx37 reduces (1) the in vitro proliferation of primary human EC; (2) the vascularization of subcutaneously implanted matrigel plugs in Cx37−/− mice or in WT using matrigel plugs supplemented with a peptide targeting Cx37 channels; (3) tumor angiogenesis; and (4) the growth of TC-1 and B16 tumors, resulting in a longer mice survival. We further document that Cx37 and Cx40 function in a collaborative manner to promote tumor growth, inasmuch as the injection of a peptide targeting Cx40 into Cx37−/− mice decreased the growth of TC-1 tumors to a larger extent than after loss of Cx37. This loss did not alter vessel perfusion, mural cells coverage and tumor hypoxia compared to tumors grown in WT mice. The data show that Cx37 is relevant for the control of EC proliferation and growth in different tumor models, suggesting that it may be a target, alone or in combination with Cx40, in the development of anti-tumoral treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth

Sathiyanadan

Alonso

Domingos-Pereira

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported that the mechanism of metastasis in bladder cancer is associated with tumour angiogenesis (5,22). Tumours become angiogenic through numerous methods, including outgrowth and sleeve-in angiogenesis, angiogenesis with the recruitment of endothelial progenitor cells and angiogenic mimicry (23)(24)(25)(26). Vasculogenesis, which is associated with the recruitment of endothelial progenitor cells, is the main mechanism of tumour angiogenesis, alongside vascular sprouting.…”

Section: Discussionmentioning

confidence: 99%

An angiogenesis‑related lncRNA signature for the prognostic prediction of patients with bladder cancer and LINC02321 promotes bladder cancer progression via the VEGFA signaling pathway

et al. 2022

View full text Add to dashboard Cite

The mechanism underlying bladder cancer metastasis is associated with tumor angiogenesis. The present study aimed to evaluate the predictive role and value of an angiogenesis-associated long non-coding (lnc)rna signature in patients with bladder cancer and the role of long intergenic non-coding rna (linc)02321 in the progression of this malignancy. angiogenesis-related lncrnas were screened using Pearson correlation analysis and the signaturewas constructed using cox regression analysis and evaluated using the receiver operating characteristic curve. linc02321, which expressed the largest difference in bladder cancer, was screened using reverse transcription-quantitative Pcr. The role of linc02321 in the malignant progression of bladder cancer was evaluated using Transwell, wound healing and cell counting Kit 8 assays. a total of six angiogenesis-associated lncrnas (uSP30-aS1, linc02321, PSMB8-aS1, KrT7-aS, linc01767 and ociad1-aS1) were identified as candidates for the prognostic signature using Cox regression analysis. The overall survival of patients in the low-risk group was significantly longer compared with that in the high-risk group, with the highest area under the curve value being 0.807. a nomogram was constructed based on the traditional clinical indicators (age, sex, grade, american Joint committee on cancer stage) and risk score of patients. compared with the traditional clinical indicators, the risk score demonstrated better clinical prediction capacity for predicting the prognosis of patients with bladder cancer. The cancer Genome atlas prediction and rT-qPcr experimental results demonstrated that only linc02321 was highly expressed in bladder cancer tissue and promoted the proliferation, invasion, migration and cisplatin resistance of the malignancy. Gene set enrichment, Pearson's correlation analysis and experimental results demonstrated that the VeGFa signalling pathway may be involved in the linc02321-regulated progression of bladder cancer. in conclusion, the six angiogenesis-associated lncrna signatures reported in the present study may be used to predict the prognosis of patients with bladder cancer, and linc02321 promoted malignant progression of bladder cancer via the VeGFa signalling pathway.

show abstract

“…To better understand the role of genes involved in tumor angiogenesis, CRISPR/Cas9 technology has been successfully used as well. Hariprabu et al reviewed the current applications of CRISPR/Cas9 technology in tumor angiogenesis research for the purpose of cancer treatment, with a focus on the possibility to create KO models to study growth factors, cytokines, kinases and integrins involved in the angiogenesis switch as possible anti-angiogenic targets [ 139 ].…”

Section: Crispr and Cancermentioning

confidence: 99%

Ten Years of CRISPRing Cancers In Vitro

Capoferri

Filiberti

Faletti

et al. 2022

Cancers

View full text Add to dashboard Cite

Cell lines have always constituted a good investigation tool for cancer research, allowing scientists to understand the basic mechanisms underlying the complex network of phenomena peculiar to the transforming path from a healthy to cancerous cell. The introduction of CRISPR in everyday laboratory activity and its relative affordability greatly expanded the bench lab weaponry in the daily attempt to better understand tumor biology with the final aim to mitigate cancer’s impact in our lives. In this review, we aim to report how this genome editing technique affected in the in vitro modeling of different aspects of tumor biology, its several declinations, and analyze the advantages and drawbacks of each of them.

show abstract

CRISPR/Cas9 in cancer therapy: A review with a special focus on tumor angiogenesis

Cited by 14 publications

References 138 publications

Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth

Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth

An angiogenesis‑related lncRNA signature for the prognostic prediction of patients with bladder cancer and LINC02321 promotes bladder cancer progression via the VEGFA signaling pathway

Ten Years of CRISPRing Cancers In Vitro

Contact Info

Product

Resources

About